Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Damora Therapeutics granted stock options to new hires as inducement awards under its 2022 Inducement Plan and Nasdaq Rule 5635(c)(4).

Rhea-AI Summary

Damora Therapeutics (DMRA) granted equity inducement awards to three newly hired non-executive employees on September 1, 2026, under Nasdaq Listing Rule 5635(c)(4). The awards were approved by the company’s independent Compensation Committee as material inducements to the employees’ acceptance of employment.

The inducement grants consist of options to purchase an aggregate of 135,400 ordinary shares, each with a 10-year term and an exercise price of $28.18 per share. All options vest 25% on the first anniversary of each employee’s start date, with the remaining 75% vesting in equal monthly installments over the following 36 months. The options are granted pursuant to the company’s 2022 Inducement Plan and individual option award agreements.

Market Context

A prior August 3 inducement-grant announcement coincided with a 5.11% 24-hour move, adding event-spe...

Analysis

A prior August 3 inducement-grant announcement coincided with a 5.11% 24-hour move, adding event-specific historical context. Platform records also showed 245 shares sold by the General Counsel, a governance-context risk to monitor.

Key Figures

New employees: 3 employees Grant date: September 1, 2026 Nasdaq rule: 5635(c)(4) +5 more

8 metrics

New employees 3 employees Recipients of September 1, 2026 grants

Grant date September 1, 2026 Date of equity award grants

Nasdaq rule 5635(c)(4) Listing rule cited for inducement grants

Shares under option 135,400 ordinary shares Aggregate shares subject to options

Option term 10 years Term of the inducement options

Exercise price $28.18 per share Exercise price of the options

Initial vesting 25% Vests on the first anniversary of each employee’s start date

Remaining vesting period 36 months Equal monthly installments after the first anniversary

Historical Context

5 past events · Latest: Aug 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 10	Q2 earnings	Positive	+2.5%	Reported Q2 results, clinical initiation, cash runway, and upcoming regulatory milestones.
Aug 05	Phase 1 trial	Positive	+2.7%	Initiated global Phase 1/1b CLARITY-101 trial after health authority approvals.
Aug 03	Inducement grants	Neutral	+5.1%	Granted options to six newly hired non-executive employees under Nasdaq Rule 5635(c)(4).
Jul 17	Redomestication	Neutral	+4.1%	Completed Delaware-to-Cayman conversion without changing Nasdaq ticker or trading continuity.
Jul 01	Inducement grants	Neutral	+10.7%	Granted options to nine newly hired non-executive employees under Nasdaq Rule 5635(c)(4).

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

All five selected prior news events were followed by positive 24-hour reactions, including neutral corporate announcements.

Key Terms

inducement grants, Nasdaq Listing Rule 5635(c)(4), exercise price, option award agreement

4 terms

inducement grants financial

"The inducement grants were approved by Damora’s independent Compensation Committee"

Inducement grants are special awards of shares or stock options given to new employees to encourage them to join a company or accept a new role. They act like a welcome bonus, providing an extra incentive to attract talent. For investors, these grants can impact a company's costs and share structure, influencing the value of their investments.

Nasdaq Listing Rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"with a 10-year term and an exercise price of $28.18 per share."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

option award agreement financial

"the terms and conditions of an option award agreement."

A written contract that grants an individual the right to buy company shares at a set price under specific conditions, like how many options they get, when they can exercise them, and when they expire. Think of it like a ticket that becomes valid only after certain milestones; it matters to investors because these agreements affect how many shares may enter the market, management incentives, and a company’s future earnings per share and dilution.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to three newly-hired, non-executive employees on September 1, 2026. The inducement grants were approved by Damora’s independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals’ acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grants consist of options to purchase an aggregate of 135,400 Damora ordinary shares with a 10-year term and an exercise price of $28.18 per share. All of the options vest as to 25% on the first anniversary of the employees’ start date and in equal monthly installments for the following 36 months. The inducement grants are subject to the terms and conditions of the 2022 Damora Therapeutics, Inc. Inducement Plan, and the terms and conditions of an option award agreement.

About Damora Therapeutics

Damora Therapeutics is an innovative biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. We are advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. With multiple programs with best-in-class potential on track to enter clinical development in 2026, our goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. For more information, visit www.damoratx.com or follow us on LinkedIn.

Investor/Media Contact:
Jim Baker
Chief Corporate Affairs Officer
Investors: investors@damoratx.com
Media: media@damoratx.com

FAQ

What equity inducement grants did Damora Therapeutics (DMRA) announce for new employees?

Damora Therapeutics announced stock option inducement grants to three newly hired non-executive employees. The awards cover an aggregate of 135,400 ordinary shares, have a 10-year term, and carry an exercise price of $28.18 per share, granted under its 2022 Inducement Plan.

What are the vesting terms of the new inducement stock options at Damora Therapeutics (DMRA)?

The inducement stock options vest 25% on the first anniversary of each employee’s start date. The remaining 75% vests in equal monthly installments over the next 36 months, subject to the terms of the 2022 Inducement Plan and the option award agreements.

Under which Nasdaq rule were Damora Therapeutics (DMRA) inducement grants made?

The inducement grants were made in accordance with Nasdaq Listing Rule 5635(c)(4). The company states that the awards were approved by its independent Compensation Committee as material inducements to the new employees’ acceptance of employment.

How many new employees received inducement stock options from Damora Therapeutics (DMRA)?

Three newly hired non-executive employees received the inducement stock option grants. In total, they were granted options to purchase an aggregate of 135,400 ordinary shares, subject to the terms of Damora’s 2022 Inducement Plan and individual option agreements.